1. Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma
- Author
-
Yih Jyh Lin, Hung Wen Tsai, I-Chin Wu, Ih-Jen Su, Pin-Nan Cheng, Ting-Tsung Chang, Chia Jui Yen, Han Chieh Wu, Shih Huang Chan, and Wenya Huang
- Subjects
Male ,0301 basic medicine ,Pathology ,Necrosis ,Biopsy ,Administration, Oral ,medicine.disease_cause ,Gastroenterology ,0302 clinical medicine ,ground glass hepatocytes ,Medicine ,Sequence Deletion ,medicine.diagnostic_test ,Liver Neoplasms ,Fatty liver ,Lamivudine ,hepatocellular carcinoma ,cccDNA ,Middle Aged ,Viral Load ,Liver ,Oncology ,Hepatocellular carcinoma ,Female ,030211 gastroenterology & hepatology ,DNA, Circular ,medicine.symptom ,Viral load ,Research Paper ,medicine.drug ,Adult ,Hepatitis B virus ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Guanine ,Adolescent ,Organophosphonates ,Antiviral Agents ,Young Adult ,03 medical and health sciences ,Hepatitis B, Chronic ,Internal medicine ,Drug Resistance, Viral ,Humans ,Amino Acid Sequence ,Protein Precursors ,Hepatitis B Surface Antigens ,anti-viral therapy ,business.industry ,Adenine ,medicine.disease ,digestive system diseases ,Fatty Liver ,030104 developmental biology ,Hepatocytes ,pre-S mutation ,business - Abstract
Ground glass hepatocytes (GGHs) have been shown to predict the development of hepatocellular carcinoma (HCC). Type I GGH and type II GGH harbor hepatitis B virus (HBV) pre-S1 and pre-S2 deletion mutants, respectively. Whether anti-HBV therapy can inhibit the expression of GGHs and potentially reduce HCC development is explored in this study. Two sets of liver specimens were included: the first contained 31 paired biopsy specimens obtained from chronic HBV patients receiving oral nucleos(t)ide analogue (NA) treatment; the second contained 186 resected liver tissues obtained from HBV-related HCC patients receiving surgery: 82 received NA before surgery and 104 did not. Compared with the baseline biopsy specimens, type I (P=0.527) and type II GGH (P=0.077) were not significantly decreased after 48 weeks of NA treatment in the first set of patients. In the second set, despite suppression of viral load (P
- Published
- 2016